Release Date: 26-Apr-2022
Global Bispecific Antibody Market Insight 2028 Report Highlights:
From last few years, antibody therapeutics is continuously expanding with promising clinical outcomes. Since then, diverse sets of antibodies have been development to target the most challenging disease areas. In recent times, bispecific antibodies have entered the market which has demonstrated several advantages over traditional monospecific antibodies. Bispecific antibodies are typically designed to possess the epitope specificity and manufacturability of a conventional monoclonal antibody but are engineered to bind two distinct targets instead of one. Development and commercialization of bispecific antibodies, to engage multiple targets using only one therapeutic, has gained significant attention recently, shifting industry focus and investments on this effective therapeutic strategy.
In January 2022, Faricimab (Vabysmo, Roche) was approved by the US Food and Drug Administration to treat wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Besides the first bsAb Catumaxomab being withdrawn in 2017, to this date, this is the fourth bispecific antibody drug on the market. Other bispecific antibodies in the market include Blinatumomab (Blincyto), Emicizumab (Hemlibra), and Amivantamab (Rybrevant). The emergence of bispecific antibodies has greatly revolutionized the management of several diseases including cancer, hemophilia, DME, and others.
The promising response of bispecific antibodies has increased the competition among pharmaceutical giants to launch their bispecific antibody constructs in the market. As per our analysis, 3-5 bispecific antibodies are expected to gain entry in the market during the forecast period. Mosunetuzumab developed by Biogen is one of the last stage bispecific antibodies. Mosunetuzumab is an investigational CD20*CD3 bispecific antibody in development for the management of follicular lymphoma. The company has recently submitted the initial market authorization application in Europe whereas the company plans to complete the BLA submission to FDA in coming months.
The key companies which are the leading in global bispecific antibody market include Roche, GenScript, Sino Biological, Creative-Biolabs, AbbVie, Kymab, AstraZeneca, Amgen, Pfizer, Novartis AG, Johnson and Johnson and ProteoGenix. These companies invest heavily in research and development to come up with different types of bispecific antibodies. They are trying to get better treatment for chronic disorder patients to increase the adoption in the market in the coming years.
The US is the most developed in all of the regions and there is a very high prevalence of cancer in the region. There is an increasing adoption of the unhealthy habits in terms of lifestyle and that is going to be a big reason for growth in the prevalence of cancer in this country. The global bispecific antibody market will see the biggest growth in the US also because of the increasing adoption of the cancer treatment here. Another factor is the presence of key players here and an increase in the research and development activities in this country. Another region where there is going to be growth is Europe. In Europe, it is Germany which leads the market as there is presence of good infrastructure related to healthcare. Well-trained medical professionals also are a factor which is leading to growth. Other regions including China, Japan, South Korea, and India are also expected to grow from high CAGR rates during the forecast period.
As per our report findings, the global bispecific antibody market is expected to surpass US$ 20 Billion by 2028 by registering high CAGR rates. The global bispecific antibody report provides an overview of the market based on key parameters such as market size, estimated sales, and key drivers and challenges. The size of the market is expected to grow on a large scale during the forecast period (2021-2028). The research offers a detailed study on the ongoing clinical trials insight segment on the basis of phase, status, region, and by indication.